Coherus BioSciences Files Definitive Proxy Statement

TL;DR

Coherus BioSciences filed its proxy statement, get ready for shareholder votes.

AI Summary

Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on December 4, 2024. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The filing does not contain specific financial details or proposals but serves as the official record for proxy solicitation.

Why It Matters

This filing is a standard regulatory requirement for public companies, indicating that Coherus BioSciences is preparing for or has held a shareholder meeting where important corporate decisions are made.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently present new financial risks or opportunities.

Key Players & Entities

• Coherus BioSciences, Inc. (company) — Registrant
• Dennis M. Lanfear (person) — Contact Person for Mailing and Business Address
• 0001104659-24-125205 (filing_id) — Accession Number

FAQ

Key Financial Figures

• $558 million — ceuticals in a transaction valued up to $558 million. Joining me today to discuss the annou
• $483.4 m — deration for an upfront cash payment of $483.4 million, plus $75 million in sales-based
• $75 million — nt cash payment of $483.4 million, plus $75 million in sales-based milestone payments. Int
• $558 m — ale price of UDENYCA franchise is up to $558 million, including an upfront payment of$
• $37.5 million — There are two sales based milestones of $37.5 million each which, if achieved, would be payab
• $3 million — .We estimate that we will pay less than $3 million in such taxes on the transaction. Seco
• $480 million — t at the beginning of 2024, Coherus had $480 million in debt across two instruments, a senio
• $250 million — struments, a senior secured facility of $250 million with effective maturity in October 2025
• $230 million — 25 and a convertible note instrument of $230 million with a maturity in April 2026. Our deb
• $38million — d cash interest burden of approximately $38million.We previously paid off a senior secured
• $38.7 million — oherus' only debt term loan will be the $38.7 million senior secured term loan, not due until
• $38.7 m — ave been decreased from $480 million to $38.7 million, a reduction of 92%, and our annu
• $38 million — tions will have been reduced from about $38 million to about$5 million, a reduction of abou
• $5 m — reduced from about $38 million to about$5 million, a reduction of about 87%. I wou
• $50 million — t closing, we will pay 40 – about $50 million to buyout the royalty of UDENYCA net sa

Filing Documents

• tm2429853d4_defa14a.htm (DEFA14A) — 100KB
• 0001104659-24-125205.txt ( ) — 102KB

forward-looking statements

forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties, including risks and uncertainties about our ability to complete the divestiture on a timely basis or at all, and risks and uncertainties inherent in the clinical development process that are discussed in our press release that we issued today, as well as the documents that we filed with the SEC from time to time, including the proxy statement of Coherus, which will be mailed or otherwise disseminated to Coherus stockholders when it becomes available.

Forward-looking statements provided on the call today are made as of

Forward-looking statements provided on the call today are made as of this date, and we undertake no duty to update or revise any forward-looking statements. With that, Denny. I'll now turn the call over to you. Dennis M. Lanfear Thank you, Jodi. Good morning, everyone, and thank you for joining us on our call.Let me first walk through the details of the transaction and why it's consistent with our overarching strategy. As we disclosed earlier today, Coherus is divesting the UDENYCA franchise to Intas.In consideration for an upfront cash payment of $483.4 million, plus $75 million in sales-based milestone payments. Intas will receive our global rights to the UDENYCA family of commercial products, including the UDENYCA prefilled syringe, the UDENYCA autoinjector and UDENYCA ONBODY. Let me describe for you the rationale for the transaction. This transaction represents the successful completion of our long-term strategy to focus our commercial and R&D resources on immuno-oncology, on our PD-1 LOQTORZI and novel combinations of LOQTORZI with a number of agents. As you know, since in-licensing our LOQTORZI in early 2021 from Junshi, we have pursued an overarching strategy to enhance long-term shareholder value and leveraging our biosimilar business to build a highly competitive and sustainable, innovative oncology franchise. After closing the Surface Oncology acquisition just over a year ago and then divesting CIMERLI and YUSIMRY, this divestiture is a definitive step in that direction. Secondly, this transaction allows us to monetize and redeploy the significant value we have created with our UDENYCA franchise to maximize the opportunity ahead for our I-O portfolio. The UDENYCA ONBODY is a highly competitively positioned, raising the brand above others and a catalyst for greater sales.But to realize the franchise's maximal long-term value, a larger, more global organization with multiple biosimilar products in the portfolio is required.There is perhaps grea

View Full Filing

View this DEFA14A filing on SEC EDGAR